Osteosarcoma Global Market Report 2025

The osteosarcoma market size has grown strongly in recent years. It will grow from $0.71 billion in 2024 to $0.76 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to increasing cancer awareness, improved treatment options, a rise in bone cancer incidence, advancements in healthcare infrastructure, growth in research and clinical trials, and the development of targeted therapies and immunotherapies.

The osteosarcoma market size is expected to see strong growth in the next few years. It will grow to $0.99 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to the rising adoption of personalized medicine, increasing awareness of rare cancers, growing government and private sector funding for research, a rising incidence of genetic mutations, and the potential for improved treatment outcomes with immunotherapy. Key trends expected during this period include the development of targeted therapies, advancements in immunotherapies, the adoption of personalized medicine, progress in gene editing techniques, innovation in chemotherapy drugs, improvements in diagnostic imaging technologies, and advancements in surgical techniques.

The increasing prevalence of cancer is expected to drive the expansion of the osteosarcoma market in the coming years. Cancer is a disease marked by the uncontrolled growth and spread of abnormal cells, which can invade and damage healthy tissues. Several factors contribute to the rising incidence of cancer, including an aging population, lifestyle changes, environmental exposures, infections, and genetic predisposition. Osteosarcoma treatment plays a crucial role in advancing therapeutic strategies, improving early detection techniques, and deepening the understanding of bone cancer. These developments lead to better patient care, improved survival rates, and the creation of more effective therapies. For example, in May 2024, the National Cancer Institute, a US-based government agency, reported that in 2022, approximately 20 million new cancer cases and 9.7 million cancer-related deaths were recorded worldwide. Projections indicate that these numbers could increase to 29.9 million new cases and 15.3 million deaths annually by 2040. Consequently, the rising prevalence of cancer is fueling the growth of the osteosarcoma market.

Major companies in the osteosarcoma market are prioritizing the development of advanced drugs with orphan drug designation to enhance treatment effectiveness, minimize side effects, and improve survival outcomes for patients. Orphan drug designation is a special status granted by regulatory agencies to drugs or biologics designed to treat rare diseases, offering benefits such as tax incentives, clinical trial support, and extended market exclusivity. For instance, in April 2024, Lisata Therapeutics Inc., a US-based pharmaceutical company, announced that its investigational drug LSTA1 received orphan drug designation from the US Food and Drug Administration (FDA). LSTA1 is designed to activate a novel uptake pathway, enhancing drug penetration and accumulation in osteosarcoma tumors while potentially modifying the tumor microenvironment to improve responsiveness to immunotherapies.

In May 2024, Telix Pharmaceuticals Limited, an Australia-based biotechnology company, acquired QSAM Biosciences Inc. for an undisclosed amount. This acquisition is intended to expand Telix Pharmaceuticals’ oncology portfolio, reinforce its expertise in targeted cancer therapies, and strengthen its capabilities in rare disease treatments, particularly osteosarcoma. QSAM Biosciences Inc. is a US-based company specializing in osteosarcoma drug development.

Major players in the osteosarcoma market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, AstraZeneca PLC, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Baxter International Inc., Hikma Pharmaceuticals PLC, Spectrum Pharmaceuticals Inc., Mylan N.V., Bellicum Phamaceuticals Inc., ADVAXIS Inc., Iovance Biotherapeutics Inc.

North America was the largest region in the osteosarcoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in osteosarcoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the osteosarcoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Osteosarcoma is a malignant tumor that develops in bone-forming cells, primarily affecting the long bones of the body. It most commonly impacts teenagers and young adults, causing symptoms such as pain, swelling, and difficulty in movement.

The primary types of osteosarcoma include intramedullary osteosarcoma, juxtacortical osteosarcoma, and extraskeletal osteosarcoma. Intramedullary osteosarcoma, the most common form, affects long bones such as the arms and legs. Originating in the bone marrow, it grows and spreads rapidly, often leading to fractures or swelling, particularly in teenagers and young adults. Treatment options include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. It is used for both pediatric and adult patients and is distributed through online and offline channels. The disease is managed in various settings, including hospitals and clinics, diagnostic centers, and academic and research institutions.

The osteosarcoma market research report is one of a series of new reports that provides osteosarcoma market statistics, including the osteosarcoma industry's global market size, regional shares, competitors with an osteosarcoma market share, detailed osteosarcoma market segments, market trends and opportunities, and any further data you may need to thrive in the osteosarcoma industry. This osteosarcoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The osteosarcoma market consists of revenues earned by entities by providing services such as diagnostic services, and supportive care solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The osteosarcoma market also includes sales of methotrexate, doxorubicin, prosthetic implants, and immune checkpoint inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.